Table 1. Demographic and clinical characteristics of study cohorts.
| Study group | Mean age–years±SD | Male sex–no.(%) | White race–no.(%) | Disease duration–years±SD | Post-kidneytransplant–no.(%) | Immunosuppressivetherapy–no. (%) | ACEI or ARBtherapy–no. (%)1 |
| IgAN (n = 99) | 42.3±13.4 | 63 (64) | 98 (99) | 7.3±7.3 | 28 (28) | 49 (50) | 79 (80) |
| Unaffected control (n = 96) | 43.8±12.7 | 55 (57) | 94 (98) | – | – | – | – |
| Celiac disease (n = 30) | 46.9±16.2 | 11 (37) | 30 (100) | – | – | – | – |
1
ACEI: Angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker.